Denmark’s food agency has recalled three South Korean spicy instant ramen noodle products – warning consumers they are so hot they might cause “acute poisoning”.

The Samyang Foods products being withdrawn are Samyang Buldak 3x Spicy & Hot Chicken, 2x Spicy & Hot Chicken and Hot Chicken Stew.

The agency issued the warning on Tuesday and said the products were being recalled because the levels of total capsaicin in a single pack of all three noodle products “are so high that they pose a risk of the consumer developing acute poisoning”.

“If you have the products, you should discard them or return them to the store where they were purchased,” the agency said.

It emphasised the warning for children, urging parents to contact a Danish helpline if their youngsters appeared to show “acute symptoms”.

Capsaicin is the substance found in chilli peppers that gives them their hot and spicy kick.

Follow Sky News on WhatsApp

Keep up with all the latest news from the UK and around the world by following Sky News

Tap here

Samyang Foods said it was the first time the company’s products had been recalled because they were deemed too spicy.

“Currently, the products are being exported around the world, but this is the first time they have been recalled for this reason,” a spokesperson for the company told the AFP news agency.

It added that it would work to better understand local regulations in export markets.

Read more from Sky News:
Man who spiked daughter’s friends’ drinks at sleepover jailed
Celine Dion took near-deadly doses of Valium to ease spasms

Samyang Foods was established in 1961 and brands itself as the first firm in the country to produce instant noodles.

Its headquarters are in the South Korean capital, Seoul.

Articles You May Like

MRI on Mariners’ Rodriguez comes back clean
Trump shooting ‘an extraordinary moment’ in already deeply anxious times
Thompson wins first PGA Tour title at John Deere
Tesla starts selling software range unlocks for recent Model Y RWD
Microsoft drops its observer seat on OpenAI board amid regulatory scrutiny